Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No they weren't friends or relatives lol. Not that I can tell.
Some were in labs, some were in the factory / warehousp, some were in the offices. They were doing stuff. Not sitting around eatting or something. Don't know what you want to hear. Not like they divulged whatever projects the were working on
Don't get me wrong man. I've almost written off this as an expensive lesson. I'd be happy to break even and move on at this point
If I were buying NOW rather than when I did though, I'd be extremely up beat.
Sorry 4 products. They only had one NDA for approval at FDA and it's got a path forward. Many drug companies get rejections and still get drugs approved. Most of the generics have been subject to the FDA backlog. We will likely see some more of those come up.
Historically the cash burn has been good. Recently we've seen an increase. Over the last er though plenty has happened. Podras trials look to have started, rexista hap has officially started, some of the pending generics have had additional studies done, the studies to get the approved ones in European markets have started. I mentioned from the tour last year they were expanding manufacturing capacity. So things are happening and they cost money.
To say they have a history of burning cash and not getting anything approved isn't accurate though. It's a growing biotech company. Again they haven't had flawless execution. Plenty could've been done differently. But hindsight is 20/20.
The company that has obtained 5 approvals so far, has had a historically low cash burn rate.
I think we seem to forget that this is a newer biotech. Most have these problems.
I'm not saying they have had perfect execution but that generalization isn't accurate.
In what sense are you comparing it to?
What news?
Looks like some buying happening
Great they can post the next PR in a few days saying "we're still working on it"
My beef is the same people saying the same.things 10 times in a row.
Well that was last year. They gave very specific guidance this year. Something we all wanted. We got what we wanted there and we're given a timeline. Freaking out before reaching the deadline does nothing expect making one appear irrational. We have till end of June so expect news by end of June.
If you want something in the meantime then make greater efforts to contact the company.
Did they or did they not say when to expect results regarding podras?
Also those bonuses are the existing warrants they get with a strike price of $3.2 so if we see those levels again. We're all doing ok. But again.... A simple phone call clears up a lot of issues
Not giving you info? Sorry what was the guidance again? There was a timeline attached to that and they have till the end of June. That's your news and guideline.
If what they said doesn't materialize by then, go nuts. But repeating the same thing over and over is useless. Want an update on it? Call them. But don't say they never said anything.
Look guys, I'm in the red as much as anyone here. I'm just as pissed.
But how many people here bashing management took the time to call them to get clarification? We just keep posting the same stuff over and over shitting on them.
I think we can all agree somethings could've been done differently and better.
But we got the guidance and for all intents and purposes they appear to be on track. So we will know by end of June how this year will go likely. So let's wait for then.
Maybe it keeps the shorts blind too?
Did you ask him that when you spoke to him?
Guys do you really think Andrew would come on board to just secretly sell the company? Things are happening. If they're telling the truth and are on track to meet their guidance we should see news soon.
I'm not an all roses guy but realistically the company is still in operation. We've got till end of June for some major events. Let's cross our fingers.
What's says they haven't started? Maybe they have. If they're on track to deliver on guidance then they must of started. The ER mentioned cost related to studies
A worth while question to ask. IF you could sell it for say 20 Mil? That can fund the company for 1.5 years which should be enough time to get Rexista to market and and maybe license PODRAS?
Seriously make an attempt to call him again. Leave a few messages he will get back. Probably have to hound him a bit.
Try try again.
From PAR's q4 2017
Revenues of $499 million, a 43 percent decrease compared to fourth-quarter 2016; this decline was primarily attributable to the loss of marketing exclusivity in the first half of 2017 for the first-to-file products ezetimibe tablets and quetiapine ER tablets. Also contributing to the decline were
The U.S. Generics Base business revenues decreased 37 percent compared to fourth-quarter 2016; this decrease primarily resulted from the impact of 2016 and 2017 competitive events, previously announced product discontinuances and the continued impact of pricing due to consolidation among our trade accounts.
They're getting hammered too in US generics.
So I'm a little mum on how drug pricing works,
But I was told its the discounts and what not that Par had to offer.
We also know the bloomberg sales numbers are not very accurate as we've seen in the past.
Call him and leave a message. He will call you back
We should be hearing about podras and rexista before june 30th. Said they are on track to meet guidance issued earlier in the year which was 1h2018.
Options are being explored with MNK as even they (MNK) admit they've failed miserably.
I suggest you call him. He is fairly personable and does try to answer questions. Bit difficult to get ahold of. But leave him a few messages on his voicemail and he will get back to you.
So in terms of revenue drop. I was informed that Par faced increased pricing pressure to keep its marketshare.
Spoke to Andrew today and he said they're still on track to meet the guidance given. So that means we should hear about Podras and rexista hap studies by end of June.
Patient. I've called twice and emails.
Well I've sent 2 emails and left messages on both his work and cell and not getting any calls back.
They have the hearing still Christ.
We must have different definitions of warp speed. I'd be happy with cruise control. We're going to miss the guidance they issued soon.
Easy to say for the guys entering now.
Let me be clear. I don't think it's a good idea nor a feasable one. That was the point I was making
The reality is it's not feasible. A Pharmacy maybe services how many people? 5,000 people? 10,000? 100,000 Individual people?
A search shows roughly 11% of children are diagnosed with ADHD.
Let's go with the high number even though I think it's ridiculous that a individual pharmacy has 100k diff patients.
Out of that 100k let's assume half are kids, likely less, but we'll say 50k. Of those 50k 11% are ADHD diagnosed means 5,500 prescriptions. But we can't even assuming that all those patients are treated with Focilian so then what? Something like 50 different drugs for ADHD, what if someone's health care plan covers the original and the patient doesn't want the generic, etc etc.
You would need hundreds of pharmacies. Just not feasible
Shawn Graham is the former premier of the province of New Brunswick in Canada. He's done several trade missions to China for the province and was on the last trip with IPCI. He's in some of the photos.
I agree. Put a condition that is meaningful on it. I'm all for rewarding good work. It has to mean more than "horay we got the paperwork right so it got approved" because the ANDAs are useless unless partnered and sold. Which we're not seeing. Attach the bonuses to meaningful revenue growth.
I want to see an act of faith and leadership from management. I would like to see Board of directors make significant purchases of stock on open market at this time and forgo their bonuses untill profitability is obtained. Lead by example.
We had 10 leadership principals we followed which I think would help IPCI if the adopted them.
be proficient;
know yourself and seek self-improvement;
seek and accept responsibility;
lead by example;
provide direction;
know and care for your subordinates;
develop the potential of your subordinates;
make sound and timely decisions;
build the team and challenge their abilities; and
communicate and keep your team informed;
As you can see, management is failing at just about all of those.
You know what pisses me off the most. Its the balls to ask for an extension for the options and bonuses. I get some of the problems were not their fault and beyond their control. But it's easy for them to recoup their losses with another bonus or stock option at shareholders expense.
I've learnt a thing or two about leadership with 17 years of military experience. And one thing you do as a leader is share in the hardships of those you're leading.
You want your bonuses? Then get the share price back up and execute on your plan you proposed. When you get the share price over $2 again you can give yourself a pat on the back and get a bonus. Because voting yourself an extension is disgusting when compared with the performance.
Sorry for the useless post that will likely be deleted. But had to rant.
This is new. Not that it matters much the way the generics are going.
Trazodone hydrochloride extended-release tablets
Oleptro™
Depression
ANDA application for commercialization approval for 2 strengths under review by FDA
The only thing I've gathered that was positive is that it looks like they paid for Rexista trials and the continuing uttering of China. Something better come from China soon.
Sigh..... So generics are tanking. Scrap all of them and only focus on the ones signed with MNK.
Put everything else to the NDA's and keep your fingers crossed. Other than that tomorrow is going to suck.
Mike I like to give people the benefit of the doubt. I'm assuming with the latest offerings, er's and other stuff they're to busy to answer our emails. But we'll see if there are some answers here.
Have you tried calling? I've gotten better luck calling lately.
Well thats my main question I'm wondering about. From how I read MNK report its not included in the sale. Just internally manufactured generics. But again that doesn't explain why no penetration. Unless maybe IPCI is having manufacturing issues? But that's not what was said at the meeting. So who knows. I've emailed Andrew twice and he has yet to reply.
I'm waiting for the ER before I phone. I'm hoping we see an improvement or at least an explanation.